11 hasil untuk "Gary T. Ferguson"

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study

Edward M. Kerwin; Gary T. Ferguson; Mindy Mo dkk.

Respiratory Research, Vol. 20 No. 1 · 2019 · Inggris · DOAJ Scopus

Abstract Background Long-term use of inhaled corticosteroids (ICSs) has been associated with increased risk of bone and ocular comorbidities. We evaluated the effects of the triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI), formulated using…

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

Sanjay Sethi; James F. Donohue; Gary T. Ferguson dkk.

Therapeutic Advances in Respiratory Disease, Vol. 14 · 2020 · Inggris · DOAJ Scopus

Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for patients with persistent chronic obstructive pulmonary disease (COPD) exacerbations on bronchodilator monotherapy. In this prespecified…

COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy

Peter M. A. Calverley; Alberto de la Hoz; Wenqiong Xue dkk.

COPD, Vol. 17 No. 5 · 2020 · Inggris · DOAJ Scopus

The American Thoracic Society guidelines recommend long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilation over LAMA or LABA monotherapy as maintenance therapy for patients with chronic obstructive pulmonary disease suffering from dyspnea or exercise intolerance…

Goals of COPD treatment: Focus on symptoms and exacerbations

Claus Franz Vogelmeier; Miguel Román-Rodríguez; Dave Singh dkk.

Respiratory Medicine · 2020 · Inggris · OpenAlex Scopus

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies

Gary T. Ferguson; Jill Karpel; Nathan Bennett dkk.

npj Primary Care Respiratory Medicine, Vol. 27 No. 1 · 2017 · Inggris · DOAJ Scopus

…sleep disturbance, is crucial to enhancing patients’ quality of life. Gary Ferguson at the Pulmonary Research Institute of Southeast Michigan, together with other scientists across the USA and Germany, analysed data from four large-scale studies to evaluate the efficacy of STIOLTO Respimat, a…

Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Fernando J. Martinez; Brian J. Lipworth; Klaus F. Rabe dkk.

Respiratory Research, Vol. 21 No. 1 · 2020 · Inggris · DOAJ Scopus

Abstract Background The Phase III PINNACLE studies assessed the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), a dual long-acting bronchodilator for chronic obstructive pulmonary disease (COPD). Here we present a pre-specified pooled analysis of…

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Fernando J. Martínez; Klaus Friedrich Rabe; Gary T. Ferguson dkk.

American Journal of Respiratory and Critical Care Medicine · 2020 · Inggris · OpenAlex Scopus

Abstract Rationale In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause…

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Klaus Friedrich Rabe; Fernando J. Martinez; Gary T. Ferguson dkk.

New England Journal of Medicine · 2020 · Inggris · OpenAlex Scopus

BACKGROUND: -agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking. METHODS: In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two…

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Gary T. Ferguson; Nicola Brown; Chris Compton dkk.

Respiratory Research, Vol. 21 No. 1 · 2020 · Inggris · DOAJ Scopus

Abstract Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy administered via single or multiple inhalers in patients with chronic obstructive pulmonary disease (COPD) has not been evaluated…

Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Colin Reisner; Leonardo M. Fabbri; Edward M. Kerwin dkk.

Respiratory Research, Vol. 18 No. 1 · 2017 · Inggris · DOAJ Scopus

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Bartolome R. Celli; Marc Decramer; Jadwiga A. Wedzicha dkk.

European Respiratory Review, Vol. 24 No. 136 · 2015 · Inggris · DOAJ Scopus

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and…